Last updated: 11/07/2018 13:46:28
ECT and paroxetine/imipramine combination treatment in depressive states. A clinical study of the safety of co-administration of ECT and paroxetine or imipramine, and relapse prevention in the maintenance phase.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: ECT and paroxetine/imipramine combination treatment in depressive states. A clinical study of the safety of co-administration of ECT and paroxetine or imipramine, and relapse prevention in the maintenance phase.
Trial description: ECT and paroxetine/imipramine combination treatment in depressive states. A clinical study of the safety of co-administration of ECT and paroxetine or imipramine, and relapse prevention in the maintenance phase.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
A comparison of paroxetine and imipramine in six months continuation therapy post ect. Bech, P, Lauritzen, L, Odgaard, K, Clemmensen, L, Lund, M, and Ohrstom, J 10th World Congress of Psychiatry 8/23/1996 Madrid; Spain
A comparison of paroxetine and imipramine in six months continuation therapy post ect. Bech, P, Lauritzen, L, Odgaard, K, Clemmensen, L, Lund, M, Ohrstom, J, and Black, C 8th Congress of the Association of European Psychiatrists/Annual Meeting of the Royal College of Psychiatrists 7/7/1996 London; UK
Bech P et al. A comparison of paroxetine and imipramine in 6 month continuation study post ECT. Acta Psychiatr. Scan 1996; 94:241-251
Relapse prevention by means of paroxetine in ect-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Lauritzen, L., Odgaard, K., Clemmesen, L., Lunde, M., Ohrstrom, J., Black, C., and Bech, P. Acta Psychiatr Scand 96; 94(4):241-51
Medical condition
Depressive Disorder
Product
paroxetine
Collaborators
Not applicable
Study date(s)
October 1989 to Invalid Date
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website